Treatment meglitinides

Meglitinide contains a benzamide group. Meglitinide-related compounds such as nateglinide are non-sulfonylurea oral hypoglycemic drugs used in the treatment of type 2 (non-insulin dependent) diabetes mellitus. 

Insulin Exenatide is not a substitute for insulin in insulin-requiring patients. Do not use exenatide in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. The concurrent use of exenatide with insulin, thiazolidinediones, D-phenylalanine derivatives, meglitinides, or alpha-glucosidase inhibitors has not been studied. 

NPH insulin or long-acting insulin analogues at bedtime or mixed short- and long-acting insulin analogues at the main meals 2—3 times a day should be added when HbAj is >7.0% despite maximal dose of OADs. At the start of insulin treatment, obese patients stop the sulphonylurea/meglitinide and the lean patients stop metformin. 

---